Baxter International Inc - Asset Resilience Ratio
Baxter International Inc (BAX) has an Asset Resilience Ratio of 8.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Baxter International Inc (BAX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Baxter International Inc's Asset Resilience Ratio has changed over time. See Baxter International Inc (BAX) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Baxter International Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Baxter International Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.73 Billion | 8.19% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.73 Billion | 8.19% |
Asset Resilience Insights
- Limited Liquidity: Baxter International Inc maintains only 8.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Baxter International Inc Industry Peers by Asset Resilience Ratio
Compare Baxter International Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alcon AG
SW:ALC |
Medical Instruments & Supplies | 0.26% |
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN |
Medical Instruments & Supplies | 29.19% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
Annual Asset Resilience Ratio for Baxter International Inc (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Baxter International Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.84% | $1.76 Billion | $25.78 Billion | -4.45pp |
| 2023-12-31 | 11.30% | $3.19 Billion | $28.28 Billion | +5.22pp |
| 2022-12-31 | 6.07% | $1.72 Billion | $28.29 Billion | -2.73pp |
| 2021-12-31 | 8.80% | $2.95 Billion | $33.52 Billion | -9.83pp |
| 2020-12-31 | 18.63% | $3.73 Billion | $20.02 Billion | +0.30pp |
| 2019-12-31 | 18.33% | $3.33 Billion | $18.19 Billion | +6.64pp |
| 2018-12-31 | 11.69% | $1.84 Billion | $15.72 Billion | -8.14pp |
| 2017-12-31 | 19.84% | $3.39 Billion | $17.11 Billion | +1.82pp |
| 2016-12-31 | 18.02% | $2.80 Billion | $15.55 Billion | -6.54pp |
| 2015-12-31 | 24.56% | $5.15 Billion | $20.96 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $26.14 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $25.22 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $20.39 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.07 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $17.49 Billion | -- |
| 2009-12-31 | 0.00% | $0.00 | $17.35 Billion | -- |
About Baxter International Inc
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable p… Read more